Cogent Biosciences (COGT) vs Mirum Pharmaceuticals (MIRM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Cogent Biosciences (COGT) has outperformed Mirum Pharmaceuticals (MIRM) over the past year, gaining 93.1% versus a gain of 11.7%. Over five years, MIRM leads with a +375.2% price change compared with +225.5% for COGT. Mirum Pharmaceuticals is the larger company by market cap ($5.28 billion vs $5.22 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COGT | MIRM |
|---|---|---|
| Share price | $30.08 | $81.35 |
| Market cap | $5.22B | $5.28B |
| 1-day change | -0.20% | +0.88% |
| YTD return | -15.32% | +2.99% |
| 1-year return | +93.07% | +11.67% |
| 5-year return | +225.54% | +375.18% |
| EPS (TTM) | $-2.16 | $-14.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $521.31M |
| Revenue growth (YoY) | — | +54.74% |
| Net income (latest FY) | $-328.94M | $-23.36M |
| Operating margin | — | -4.25% |
| Net margin | — | -4.48% |
| 52-week high | $43.73 | $130.00 |
| 52-week low | $13.78 | $63.23 |
| Distance from 52-week high | -31.21% | -37.42% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +85.57% | +79.21% |
| Average volume | 1.90M | 695.76K |
| Shares outstanding | 173.52M | 64.93M |
| Employees | 258 | 433 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- COGT has outperformed MIRM by 81.4 percentage points over the past year.
- The two companies sit in different sectors: Cogent Biosciences in Healthcare and Mirum Pharmaceuticals in Health Care.
About Cogent Biosciences
COGT stock →Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.
Healthcare · Biotechnology · 258 employees
About Mirum Pharmaceuticals
MIRM stock →Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 433 employees
COGT vs MIRM FAQ
Which is bigger, Cogent Biosciences or Mirum Pharmaceuticals?
Mirum Pharmaceuticals (MIRM) is larger, with a market capitalization of $5.28B compared with $5.22B for Cogent Biosciences (COGT).
Which stock has performed better over the past year, COGT or MIRM?
COGT returned +93.07% over the past 12 months, compared with +11.67% for MIRM (price return, excluding dividends). Past performance does not predict future results.
Are Cogent Biosciences and Mirum Pharmaceuticals in the same industry?
No. Cogent Biosciences is in the Healthcare sector, while Mirum Pharmaceuticals is in Health Care.